Kornimate/medical-research-clean huggingface dataset:
assessment of endogenous oxalate synthesis

Conditions: Healthy; Kidney Stone; Obesity

Summary: this study aims to determine the daily rate of endogenous synthesis of oxalate using carbon 13 oxalate isotope tracer technique and a low-oxalate controlled diet.

urinary oxalate excretion is derived from both dietary sources and endogenous synthesis. this study will use low-oxalate controlled diet and intravenous infusion of the isotope tracer carbon 13 oxalate, timed with blood and urine collections, to determine the daily rate of endogenous oxalate synthesis in non-stone forming volunteers and in subjects with calcium oxalate kidney stones. a dxa scan will be used to assess body composition.

Eligibility criteria:
inclusion criteria: * mentally competent adults, able to read and comprehend the consent form * body mass index (bmi) between 18.5 and 50 kg/m2 * acceptable 24 hour urine collections (judged on screening) * good health as judged from a medical history, reported medications, and a complete blood metabolic profile * with or without history of calcium oxalate kidney stones exclusion criteria: * history of any hepatic, bowel, or endocrine disease or other condition that may influence the absorption, transport or urine excretion of ions * abnormal urine chemistries or blood metabolic profiles * poor 24 hour urine collections completed during screening, judged by 24 hour urine creatinine excretion (indicative of not collecting all urine in the 24 hour period) * pregnancy, intention to become pregnant in the near future, or lactation * aged lower than 18 or greater than 75 years * bmi lower than18.5 or greater than 50 kg/m2

Keywords: oxalate kidney stones urolithiasis nephrolithiasis urologic disease oxalate metabolism
identification of broadly hiv-1 neutralizing antibodies (bnab) in hiv-infected patients in mbeya, tanzania.

Conditions: HIV/AIDS

Summary: in natural hiv disease, a small fraction (1-2%) of infected individuals develops exceptionally high titres of hiv-1 neutralizing serum activity. antibodies isolated from these individuals have been shown to be highly active against a broad range of different hiv strains and are therefore called broadly neutralizing antibodies (bnabs). these antibodies are in fact able to prevent (s)hiv infection in animal models and therefore of great interest for the development of an hiv vaccine. information of neutralizing antibodies in patients from africa is still scarce and would be of great value in the development of adapted hiv vaccine strategies in these regions. this study aims to investigate african hiv-infected individuals, who have developed neutralizing antibodies using highly specialized laboratory methodologies.


Eligibility criteria:
inclusion criteria: 1. voluntary and informed consent 2. ≥18 years of age 3. documented hiv infection. 4. willing to consent to active tracing including home tracing exclusion criteria: 1. deficiency, rendering it difficult, if not impossible, to take part in the study or understand the information provided. this includes alcoholism, drug dependency as well as psychiatric illnesses, suicidal tendencies or any other inability. 2. prisoners 3. if within the discretion of the investigator study participation would possibly add not acceptable risk or burden to patient (e.g. significant health deficiencies, social harm) 4. unlikely to comply with protocol as judged by the principal investigator or his designate
regorafenib in taiwan metastatic colorectal cancer (mcrc) patients

Conditions: Metastatic Colorectal Cancer

Summary: regorafenib is currently the standard of care for refractory mcrc patients. pivotal studies of regorafenib have proven the efficacy and safety, with a 28-day cycle (21 days on, 7 days off) and 160 mg dose given once daily. in the clinic, patients often have some complicated condition. this study aims to perform retrospective medical chart review of mcrc patients who received regorafenib treatment in two medical centers in taiwan to examine treatment effectiveness in the routine clinical practice setting.


Eligibility criteria:
inclusion criteria: * mcrc patients who received at least one dose of regorafenib treatment exclusion criteria: * \<=20 y/o * patients who did not receive regorafenib treatment will be excluded from the analysis * patients with incomplete medical records that are deemed ineligible for analysis by investigator
individualized nutritional counselling during chemotherapy for colorectal cancer (colonut)

Conditions: Stage IV Colorectal Cancer

Summary: the purpose is to study the effect of individualized nutritional counselling compared to usual nutritional care on cross-sectional muscle area in patients with stage iv colorectal cancer during first line chemotherapy. secondary, effect on total lean body mass, treatment intensity, physical functioning, quality of life and survival will be studied.we hypothesize that patients in the intervention arm benefit from individualized nutritional counseling.


Eligibility criteria:
inclusion criteria: * age ≥18 years * stage iv colorectal cancer * scheduled for treatment with first line chemotherapy, either capox(-b), folfox(-b) or capecitabine(-b) * ct scan suitable for evaluating muscle mass at l3 level * understanding of the dutch language * able and willing to give written informed consent exclusion criteria: * chemotherapy in the previous three months * who performance status ≥ 3 * long-term high dose of corticosteroids: ≥ three weeks ≥ ten milligram prednisolon or equivalent
research on the economics of artemisinin combination therapy (acts) for the treatment of malaria

Conditions: Malaria

Summary: the objective of the react project is to evaluate the effectiveness and cost-effectiveness implications of interventions designed to improve health worker practice in providing treatment for uncomplicated malaria to febrile patients attending health facilities in cameroon and nigeria.

nigeria two interventions will be evaluated: (i) provider intervention including introducing rdts with detailed instructions, one-off training, job aides and on-the-site supportive supervisory visits and (ii) combined provider intervention \[as under (i)\]and community-based intervention (using primary and secondary schools as focal points)including school malaria events with drama, peer-health education, distribution of health education materials. types of facilities include: public primary health facilities, private pharmacies and private patent medicine dealers (pmds)in enugu state. the two sites in enugu state are: enugu urban (comprising of enugu east, enugu south and enugu north local government areas (lga) and udi lga. the impact of the interventions will be evaluated using a 3-arm stratified, cluster randomized trial with a cluster defined as a geographical community and the two study sites as the strata. the three arms of the trial are: * intervention - provider intervention * intervention - provider plus school-based malaria activities * control - expected practice (once rdts have been introduced) cameroon two interventions will be evaluated: (i) the introduction of rapid diagnostic tests (rdts) with basic provider training on malaria diagnosis and treatment; and (ii) the basic provider training \[as under (i)\] plus enhanced provider training to improve the quality of care that includes aspects of interactive self awareness, communication modules between health workers and also between health workers and patients. types of facilities include: public district hospitals, public health centres (including integrated health centres), mission hospitals and mission health centres (including integrated health centres)in yaoundé and bamenda health districts. a stratified, cluster randomized trial will be used in which health facilities are the cluster and the two study sites are the strata. the three arms of the trial are: * intervention - rdts with basic provider training; * intervention - rdts with basic plus enhanced provider training; * control - which represents current practice and neither intervention will be implemented.

Eligibility criteria:
inclusion criteria: * the patient (or their caregiver) reports that the patient is suffering from a fever or has a history of fever in this illness episode * the patient is present at the health facility exclusion criteria: * the patient is pregnant * the patient is \<6 months old * the patient has signs or symptoms of severe malaria

Keywords: cost effectiveness provider knowledge schools
correlation between clinical measurement scales for gross motor function

Conditions: Cerebral Palsy

Summary: evaluating and applying an early and consistent rehabilitation approach to children with neurological impairments requires a multidisciplinary approach that involves different specialists, including pediatricians, pediatric neurologists, professional therapists, and pediatric physical therapists. evaluation is essential to validate the judgment, monitor the source, and evaluate the mechanical function and related difficulties.


Eligibility criteria:
inclusion criteria: * children with spastic cp with the capability to keep a standing position alone for at minimum five seconds, and the grade of hypertonicity in the lower extremity varied from grade 1 to grade 2 on the modified ashworth scale with the capability to collaborate and follow directives exclusion criteria: * children were excluded if they had a serious neurological condition (epilepsy), orthopedic complications, leg surgery, botulinum toxin treatment in the lower extremity in the last 6 months before the study and suffered from advanced intellectual disability.
effects of dual-task training in individuals with alzheimer

Conditions: Alzheimer Disease

Summary: the purpose of this study is to investigate the effects of dual-task training on balance, fear of falling, cognitive functions, dual-task performance, depression and quality of life in individuals with alzheimer.

eligible participants will be randomized to control or dual-task training group.control group will receive conventional therapy generally consisted of lower and upper range of motion exercises for 30 minutes 2 times a week for 8 weeks.dual-task training group will receive exercises involving motor-cognitive dual-task exercises for 30 minutes 2 times a week for 8 weeks.each participant will be assessed before and after the 8 weeks of treatment.

Eligibility criteria:
inclusion criteria: * having been diagnosed with mild or moderate alzheimer's disease * able to walk with or without assistance * having sufficient visual and auditory ability to perform the cognitive tests * being fit to perform physical exercises * being able to participate in proposed interventions and assessments exclusion criteria: * having a neurological disorder other than alzheimer * having any musculoskeletal problems that can affect balance * having any contraindication to exercise * functional limitation or sensory impairment that may affect performance * major depression

Keywords: alzheimer fear of falling dual-task balance cognition
effect of disinfective solution as an adjunct to maintenance therapy of inflamed periodontal pockets

Conditions: Chronic Periodontitis

Summary: this study will determine whether the supplemental use of chemical pocket disinfection with scaling and root planing is more effective than scaling and root planing alone in clinically reducing periodontal probing depth (pd), reducing bleeding on probing (bop), and gaining clinical attachment level (cal). it also will assess whether chemical pocket disinfection with scaling and root planing will have an effect on biomarkers of inflammation.

the purpose of this study is to determine whether the adjunctive use of chemical pocket disinfection with scaling and root planing is more effective than scaling and root planing alone in clinically reducing periodontal probing depth (pd), reducing bleeding on probing (bop), and gaining clinical attachment level (cal). it also will assess whether chemical pocket disinfection with scaling and root planing will have an effect on biomarkers of inflammation, as indicated by presence of pro- and anti-inflammatory cytokines, compared to scaling and root planing alone. the chemical pocket disinfection therapy consists of delivering a sodium hypochlorite solution followed by a neutralizing citric acid solution to the test site. pro-inflammatory interleukin-1 beta and anti-inflammatory interleukin-1 receptor antagonist will be measured from the gingival crevicular fluid sampled from sites of interest.

Eligibility criteria:
inclusion criteria: * periodontal maintenance patients, have at least one pocket greater than or equal to 5 mm with bleeding on probing exclusion criteria: * uncontrolled diabetics * regular users of nonsteroidal antiinflammatory drugs * individuals on anti-coagulants * individuals that have used antibiotics in the previous 3 months or require prophylactic antibiotic coverage * pregnant individuals
impact of female pelvic reconstruction surgery on lower urinary tract symptoms, psychosomatic distress and sexual function

Conditions: Pelvic Organ Prolapse

Summary: to get the impact of pelvic floor reconstruction surgery on lower urinary tract symptoms, psychological distress and sexual function.


Eligibility criteria:
inclusion criteria: * women with pelvic organ prolapse, who will undergo pelvic reconstruction surgery * women who had undergone pelvic reconstruction surgeries in our hospital exclusion criteria: * pregnant woman.
role of ultrasound in inflammatory bowel disease

Conditions: Inflammatory Bowel Diseases

Summary: the aim of this article is to provide an extensive overview of the actual role of bowel ultrasound in the detection and follow-up of patients with chronic inflammatory bowel disease

the inflammatory bowel disease is a chronic bowel disorder; it can involve the whole gastrointestinal tract, but its localization in the ileum or colon is most common. the reference standard for the diagnosis of inflammatory bowel disease is ileocolonoscopy with histologic assessment. dan carter, lior h. katz, eytan bardan, eti salomon, shulamit goldstein, shomron ben horin, uri kopylov, and rami eliakim the reference standard for the detection of any complications is surgery. however, imaging techniques have an important role both in the detection/localization of c d and in the followup of c d patients. in the last few years, the technical development of ultrasound equipment, the advent of new technologies such as elastography and mostly the increased expertise of sonographers have boosted the role of bowel ultrasound in assessment of the gastrointestinal tract. in fact, bowel ultrasound is particularly attractive thanks to its widespread availability, non-invasiveness, low cost and good reproducibility, as it can be easily repeated during follow-up clara benedetta conti , mariangela giunta , daniele gridavilla , dario conte , mirella fraquelli . bowel ultrasound has become the first-line imaging technique for patients with suspected c rohn's disease because it is cheap ,less radiation effect ,it can be done more than one time for follow up these patient . some signs, for example, bowel loop elasticity (i.e., the capability of the bowel wall to collapse on the bowel lumen and return to the original size and shape after manual compression and decompression) and compressibility at probe contact and peristalsis (usually impaired), are not specific, whereas other signs, such as the characteristics of the bowel wall, are more specific. among the latter, the most important sign is bowel wall thickening (bwt) . also important are bowel wall echo pattern characteristics (bwp) , the presence of any margin irregularity and the grade of vascularity at echo color doppler or power doppler . other yet less frequent signs are the luminal alterations, such as the distension or any luminal stenosis. other possible findings outside the bowel loop are mesenteric hypertrophy , enlarged mesenteric lymph nodes and free fluid in the abdominal cavity or among the bowel loops .

Eligibility criteria:
inclusion criteria: * all patient reffered to radiology department for doing ultrasonography suspected to have bowel disease. exclusion criteria: * no patient excluded to do this process.
etanercept sfp in ra patients

Conditions: Rheumatoid Arthritis

Summary: purpose of this study is to evaluate the immunogenicity and overall safety of etanercept sfp therapy administered once weekly for 24 weeks to subjects with rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * men and women 18 years of age or older who have ra, as defined by the acr criteria for classification of ra * naïve to etanercept therapy * able to self-inject investigational product or have a designee who can do so * ethical - before any study-specific procedure, the appropriate written informed consent must be obtained exclusion criteria * receipt of corticosteroids\> 10 mg/day of prednisone (or its equivalent) during 14 days befor 1st dose of investigational product * receipt of mtx witin 30 days of 1st dose of investigational product * receipt of an other investigational drug within 30 days of 1st dose * receipt of tnf inhibitor therapy within 90 days of 1st dose * receipt of cyclophosphamide within 6 mo of 1st dose * current use of nonsteroidal anti-inflammatory drugs (nsaids) greather than the maximum recommended dose in the product info sheet * current use of insulin * gnificant concurrent medical condition

Keywords: rheumatoid arthritis etanercept enbrel amgen
safety and efficacy of ferriprox™ (deferiprone) oral solution in iron overloaded pediatric patients

Conditions: Iron Overload

Summary: * the primary objective is to assess the safety of ferriprox oral solution for the treatment of iron overload in pediatric patients with transfusion-dependent anemia. * the secondary objective is to assess the efficacy of ferriprox oral solution in reducing iron overload in pediatric patients with transfusion-dependent anemia.

this will be a multi-centre, open label, single treatment, uncontrolled study. a total of 100 iron-overloaded pediatric patients with transfusion-dependent anemia will be enrolled in the study.eligible patients will receive ferriprox (deferiprone) oral solution, 100 mg/ml, at a total daily dose of 75 mg/kg body weight or 100 mg/kg body weight, divided in three (3) doses, for 24 weeks.

Eligibility criteria:
inclusion criteria: * patients who are ≤ 10 years of age. * patients who have a confirmed diagnosis of transfusion-dependent anemia, other than blackfan-diamond anemia, and have chronic iron overload requiring chelation therapy. * patients who are in a chronic transfusion program, and who have received at least eight (8) red blood cell transfusions per year for a minimum of one year. * patients who are iron overloaded as assessed by serum ferritin concentration greater than 1000 µg/l. exclusion criteria: * patients who have a diagnosis of blackfan-diamond anemia. * patients who have experienced neutropenia/agranulocytosis (absolute neutrophil count (anc) \< 1.5 x 109/l) or thrombocytopenia (platelet count \< 50.0 x 109/l). * patients who have had previous treatment with ferriprox and presented serious adverse reaction or intolerance requiring withdrawal of ferriprox. * patients with evidence of abnormal liver function (alt level \> 3 times the upper limit of normal; entry may be delayed until values return to normal). * patients with evidence of renal failure, characterized by serum creatinine level \> 2 times the upper limit of normal; entry may be delayed until values return to normal.

Keywords: iron overload
two hypoabsorption techniques for the treatment of type iii obesity (oasis)

Conditions: Obesity, Morbid

Summary: this study aims to compare the percentage of total weight lost in long-term follow-up after two surgical interventions (sadis and oagb) in patients with morbid obesity bmi between 45-49.9.


Eligibility criteria:
inclusion criteria: * patients over 18 and under 65 who meet criteria for bariatric surgery. * maximum bmi between 45 and 50 kg/m2 and indication for surgery in a time * signature of the informed consent of the study * patients suitable for laparoscopic surgery exclusion criteria: * previous bariatric surgery * 2-stage surgery * contraindication for hypoabsorptive surgery due to previous pathology: inflammatory bowel disease, transplant recipient or transplant candidate, previous intestinal resection surgery * other associated surgical procedures in the same intervention. * conversion to laparotomy

Keywords: oagb sadis bariatric surgery
s-1/leucovorin (sl) versus slv5fu2 as the first-line treatment for elderly patients with colorectal cancer

Conditions: Colorectal Cancer

Summary: this phase ii trial on the assumption that s-1 combined with leucovorin may have better efficacy and safety than simplified 5-fu/lv infusion therapy in elderly patients with advanced colorectal cancer.

this is a randomized phase ⅱ study, in which s-1 is used in combination with leucovorin in elderly patients with advanced colorectal cancer as first-line treatment,comparing with slv5fu2 therapy. the aim of this study is to determine the efficacy and safety of s-1/lv in elderly patients in the first-line setting. the other secondary endpoints are progression free survival,overall survival, and quality of life are also evaluated.

Eligibility criteria:
inclusion criteria: * signed written informed consent * oral medication is acceptable * histologically confirmed colorectal carcinoma * male or female ≥ 65 years of age * no prior chemotherapy,radiotherapy,target therapy and immunotherapy, except adjuvant chemotherapy with an interval of ≥ 180 days) * presence of at least one target lesion measurable by ct scan or mri,within 15 days prior to trial * the lab values within 2 weeks prior to trial should meet: plt ≥7.5\*10\^4/mm3 anc≥2000/mm3 hb≥100g/l total bilirubin \< upper limit of normal level alt/ast/alp \< 2.5 x unl (\<5 x unl for patients with liver or bone metastasis) serum creatinine \< unl * performance status (ecog) 0\~1 * life expectation longer than 90 days exclusion criteria: * allergy to s-1,fluorouracil or leucovorin * any investigational agent(s) within 4 weeks prior to entry * previous or currently exposure to certain drugs which are proved to have influence on blood drug concentration * active infection * severe organ failures or diseases, including: intestinal obstruction, pulmonary fibrosis, uncontrolled diabetes mellitus,clinically relevant coronary disease, cardiovascular disorder or myocardial infarction,renal or liver failure, severe psychiatric illness,cerebral vascular disease and sever gi ulcer which need blood infusion. * uncontrolled hydrothorax,ascites and hydropericardium * multiple bone metastatic lesions * brain metastases * chronic diarrhea or digestive disfunction * previous malignancy (except colorectal cancer, history of basal cell carcinoma of skin or pre-invasive carcinoma of the cervix with adequate treatment) * strong willingness to receive surgery or highly potential to have intestinal obstruction which may need surgery intervention * other conditions that primary investigate or investigator consider to be unsuitable for the trial

Keywords: elderly patients advanced colorectal cancer chemotherapy s-1 5-fluorouracil leucovorin